Evidence map›Paper›PMID 38148017›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2023

Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.

Yasunobu Sekiguchi, Hiroki Tsutsumi, Ayumi Gomyo, Masahisa Kudo, Yoshie Iizaki, Nobuo Maseki, Machiko Kawamura, Kazuhiko Kobayashi, Yu Nishimura, Hiroaki Kanda and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasunobu SekiguchiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Hiroki TsutsumiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Ayumi GomyoDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Masahisa KudoDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Yoshie IizakiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Nobuo MasekiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Machiko KawamuraDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Kazuhiko KobayashiDepartment of Inspection Engineering, Saitama Cancer Center, Saitama, Japan.
Yu NishimuraDepartment of Pathology, Saitama Cancer Center, Saitama, Japan.
Hiroaki KandaDepartment of Pathology, Saitama Cancer Center, Saitama, Japan.
Hideaki NittaDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Hirofumi KobayashiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ImmunoconjugatesLymphoma, Large B-Cell, DiffuseAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansRituximabAntibodies, MonoclonalImmunoconjugatespolatuzumab vedotinRituximab80 years overdiffuse large B-cell lymphomaPOLARIXPola-R-mini-CHPR-mini-CHOP

Identifiers

PMID38148017
PMCPMC10861370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.